Abstract
Vaccines are the best defense available against infectious diseases. Vaccine safety is of major focus for regulatory bodies, vaccine manufacturers, public health authorities, health care providers and the public as vaccines are often given to healthy children and adults as well as to pregnant woman. Safety assessment is critical at all stages of vaccine development. Effective, clear and consistent communication of the risks and benefits of vaccines and advocacy during all stages of clinical research (including the preparation, approvals, conduct of clinical trials through the post marketing phase) is critically important. This needs to be done for all major stakeholders (e.g. community members, Study Team, Health Care Providers, Ministry of Health, Regulators, Ethics Committee members, Public Health Authorities and Policy Makers). Improved stakeholder alignment would help to address some of the concerns that may affect the clinical research, licensing of vaccines and their wide-spread use in immunization programs around the world.
Keywords: Adverse events, clinical research, communicating, pharmacovigilance, safety, vaccine introduction.
Current Drug Safety
Title:Communicating Vaccine Safety During the Development and Introduction of Vaccines
Volume: 10 Issue: 1
Author(s): Sonali Kochhar
Affiliation:
Keywords: Adverse events, clinical research, communicating, pharmacovigilance, safety, vaccine introduction.
Abstract: Vaccines are the best defense available against infectious diseases. Vaccine safety is of major focus for regulatory bodies, vaccine manufacturers, public health authorities, health care providers and the public as vaccines are often given to healthy children and adults as well as to pregnant woman. Safety assessment is critical at all stages of vaccine development. Effective, clear and consistent communication of the risks and benefits of vaccines and advocacy during all stages of clinical research (including the preparation, approvals, conduct of clinical trials through the post marketing phase) is critically important. This needs to be done for all major stakeholders (e.g. community members, Study Team, Health Care Providers, Ministry of Health, Regulators, Ethics Committee members, Public Health Authorities and Policy Makers). Improved stakeholder alignment would help to address some of the concerns that may affect the clinical research, licensing of vaccines and their wide-spread use in immunization programs around the world.
Export Options
About this article
Cite this article as:
Kochhar Sonali, Communicating Vaccine Safety During the Development and Introduction of Vaccines, Current Drug Safety 2015; 10 (1) . https://dx.doi.org/10.2174/157488631001150407110435
DOI https://dx.doi.org/10.2174/157488631001150407110435 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review
Current Pharmaceutical Design An Assessment of the Effects of Azodicarbonamide-containing Diet on Neurobehaviour, Brain Antioxidant Status and Membrane Lipid Peroxidation Status in Rats
Central Nervous System Agents in Medicinal Chemistry Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy Bovine lactoferrin as a Modulator of Neuroendocrine Components of Stress
Current Molecular Pharmacology Crisis Intervention Related to the Use of Psychoactive Substances in Recreational Settings - Evaluating the Kosmicare Project at Boom Festival
Current Drug Abuse Reviews Novel 5-HT7 Ligands as Antidepressants: Automated Synthesis of NSubstituted- N-[1-Methyl-3-(4-Methylpiperidin-1-yl)propyl]-Arylsulfonamides
Letters in Drug Design & Discovery Metabolic Changes in Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Harnessing Metabolomics for Nutrition Research
Current Pharmaceutical Biotechnology Influence of Different Substituents on Anion Binding Ability in Aromatic Hydroxyl Group Derivatives: Experiment and Theory
Current Analytical Chemistry Recent Patents of Nanodevices for Single Cell Immunological Assays
Recent Patents on Nanotechnology Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Models of Parkinson’s Disease with Special Emphasis on Drosophila melanogaster
CNS & Neurological Disorders - Drug Targets The Value of Neuroimaging Techniques in the Translation and Transdiagnostic Validation of Psychiatric Diagnoses - Selective Review
Current Topics in Medicinal Chemistry Improving Medication Adherence in Chronic Pediatric Health Conditions: A Focus on ADHD in Youth
Current Pharmaceutical Design Inhibition of the PERK-Dependent Unfolded Protein Response Signaling Pathway Involved in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment
Current Drug Delivery Pharmacogenetics of Bipolar Disorder
Current Pharmacogenomics In Silico Drug Repositioning for Chagas Disease
Current Medicinal Chemistry Recent Patents on Pharmacotherapy for Alcoholism
Recent Patents on CNS Drug Discovery (Discontinued)